As the First Coronavirus Vaccine Human Trials Begin, Manufacturer Is Already Preparing to Scale Production to Millions
and the vaccine’s developer, Moderna Therapeutics, is already thinking ahead. Although testing on the vaccine will take at least a year to complete, the work could provide valuable information about how the immune system can fight coronaviruses and could give scientists a head start if any new outbreaks of the virus were to occur.in Norwood, Mass., including president Dr.
For the first phase, Moderna shipped hundreds of vials of the test vaccine to the National Institutes of Health , which is overseeing the study in multiple centers in the US. For the next, says Hoge, “it will be several fold, maybe five-fold larger than the first phase. We are talking thousands of vials.”
That’s made possible, in part, by the non-traditional technology used to make this particular vaccine. Moderna uses mRNA, a genetic form of the virus’ genome, in its vaccine. When it’s injected into people, cells then process it so immune cells can recognize it and target it for destruction. Unlike the processes used to make most traditional vaccines, this method does not require growing huge amounts of the virus, which is time-consuming.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: Forbes - 🏆 394. / 53 続きを読む »